Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease.
Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease.
复制标题
非酒精性脂肪性肝病患者的氧化高密度脂蛋白随着纤维化进展呈阶梯状增加。
DOI：
10.3390/antiox10020239
复制
发表时间：
2021-02-04
期刊：
影响因子：
--
通讯作者：
Kotani K
中科院分区：
文献类型：
--
作者：
Miura K;Arai N;Goka R;Morimoto N;Watanabe S;Isoda N;Yamamoto H;Kotani K
非酒精性脂肪性肝病（NAFLD）患者表现出血脂异常和冠心病（CHD）的高风险。然而，在患有晚期纤维化的NAFLD患者中发现常规动脉粥样硬化脂质水平较低，其中CHD的风险极高。本研究的目的是评估NAFLD患者氧化高密度脂蛋白（oxHDL）的水平，oxHDL是一种新兴的动脉粥样硬化生物标志物。共入组了32例非NAFLD受试者和106例NAFLD患者。使用非侵入性方法对纤维化等级进行分层，包括纤维化-4指数和NAFLD纤维化评分。晚期肝纤维化患者的总胆固醇和低密度脂蛋白（LDL）胆固醇水平显著降低。相比之下，oxHDL水平在NAFLD患者中很高，并且随着纤维化的进展而逐步增加。这些oxHDL水平与HDL胆固醇水平无关，他汀类药物的使用不影响oxHDL水平。肥胖患者oxHDL水平没有增加，而低握力患者在NAFLD伴晚期纤维化患者中oxHDL水平较高。总之，oxHDL是评估NAFLD患者状态的潜在生物标志物，包括CHD和代谢/营养障碍，以及晚期肝纤维化的特定病例。
Patients with nonalcoholic fatty liver disease (NAFLD) show dyslipidemia and a high risk for coronary heart disease (CHD). However, conventional atherosclerotic lipids are found at low levels in NAFLD patients with advanced fibrosis, in whom the risk for CHD is extremely high. The aim of the present study was to evaluate the levels of oxidized high-density lipoprotein (oxHDL), an emerging atherosclerotic biomarker, in patients with NAFLD. A total of 32 non-NAFLD subjects and 106 patients with NAFLD were enrolled. The fibrosis grades were stratified using non-invasive methods, including the Fibrosis-4 index and NAFLD fibrosis score. Total cholesterol and low-density lipoprotein (LDL)-cholesterol levels were significantly low in patients with advanced liver fibrosis. In contrast, oxHDL levels were high in NAFLD patients and showed a stepwise increase as fibrosis progressed. These oxHDL levels were independent of the HDL cholesterol levels, and statin use did not influence the oxHDL levels. Obese patients showed no increase in oxHDL levels, whereas patients with a low handgrip strength showed high oxHDL levels in NAFLD with advanced fibrosis. In conclusion, oxHDL is a potential biomarker for assessing the status of patients with NAFLD, including CHD and metabolic/nutritional disturbance, and particular cases with advanced liver fibrosis.
登录
查看更多内容
影响因子：
4.2
作者：
Cohen DE;Fisher EA
通讯作者：
Fisher EA
影响因子：
13.5
作者：
Kim, Donghee;Kim, W. Ray;Kim, Hwa Jung;Therneau, Terry M.
通讯作者：
Therneau, Terry M.
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
4.6
作者：
Meng G;Wu H;Fang L;Li C;Yu F;Zhang Q;Liu L;Du H;Shi H;Xia Y;Guo X;Liu X;Bao X;Su Q;Gu Y;Yang H;Bin Yu;Wu Y;Sun Z;Niu K
通讯作者：
Niu K
影响因子：
25.7
作者：
Lee, Yong-ho;Jung, Kyu Sik;Cha, Bong-Soo
通讯作者：
Cha, Bong-Soo